Z
Zheng-Yu Jiang
Researcher at China Pharmaceutical University
Publications - 91
Citations - 2389
Zheng-Yu Jiang is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 22, co-authored 76 publications receiving 1616 citations.
Papers
More filters
Journal ArticleDOI
The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
TL;DR: The main focus of this review is on recent progress in studies of agents that target the Keap1–Nrf2–ARE pathway and the therapeutic applications of such agents.
Journal ArticleDOI
Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
Zheng-Yu Jiang,Meng-Chen Lu,Li Li Xu,Ting-Ting Yang,Xi Meiyang,Xiao-Li Xu,Guo Xiaoke,Xiaojin Zhang,Qidong You,Haopeng Sun +9 more
TL;DR: This work successfully designed and characterized the most potent protein-protein interaction (PPI) inhibitor of Keap1-Nrf2, compound 2, with K(D) value of 3.59 nM binding to Keap 1 for the first time to single-digit nanomolar.
Journal ArticleDOI
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.
TL;DR: Keap1, a substrate adaptor protein for ubiquitin E3 ligase involved in oxidative stress regulation, is identified as a novel candidate for PROTACs that can be applied in the degradation of the nonenzymatic protein Tau and peptide 1 can downregulate the intracellular Tau level in both time- and concentration-dependent manner.
Journal ArticleDOI
Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions
TL;DR: This Perspective summarizes the progress in the discovery and development of Keap1-Nrf2 PPI inhibitors, including the Keap 1-NRF2 regulatory mechanisms, biochemical techniques for inhibitor identification, and approaches for identifying peptide and small-molecule inhibitors.
Journal ArticleDOI
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown.
TL;DR: It is shown that Azo-PROTAC combines the potent protein knockdown and facile cell uptake properties of the small-molecule PROTAC with a reversible photo-switch ability, offering a promising chemical knockdown strategy based on the light-induced reversible on/off property.